PDCD1 and neoplasm: In osteosarcoma, ALKBH5 could inhibit tumor progression through epigenetic silencing of m6A-dependent pre-miR-181B-1/YAP signaling pathway (20). Furthermore, Tariq M Rana revealed that ALKBH5 regulated the response of anti-PD-1 therapy by regulating lactate in tumor microenvironment and inhibiting immune cell recruitment (23).